237 related articles for article (PubMed ID: 34976829)
1. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by
Li J; Ge S; Sang S; Hu C; Deng S
Front Oncol; 2021; 11():789014. PubMed ID: 34976829
[TBL] [Abstract][Full Text] [Related]
2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
3. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
[TBL] [Abstract][Full Text] [Related]
4. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X
Front Oncol; 2021; 11():769272. PubMed ID: 34868999
[TBL] [Abstract][Full Text] [Related]
5. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Wen Q; Yang Z; Dai H; Feng A; Li Q
Front Oncol; 2021; 11():620246. PubMed ID: 34422625
[TBL] [Abstract][Full Text] [Related]
6. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
7. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
Wu X; Huang Y; Zhao Q; Wang L; Song X; Li Y; Jiang L
EJNMMI Res; 2020 May; 10(1):51. PubMed ID: 32430866
[TBL] [Abstract][Full Text] [Related]
9. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
[TBL] [Abstract][Full Text] [Related]
10. Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics.
Jia T; Lv Q; Zhang B; Yu C; Sang S; Deng S
BMC Med Imaging; 2023 Jul; 23(1):93. PubMed ID: 37460990
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a
Ouyang ML; Wang YR; Deng QS; Zhu YF; Zhao ZH; Wang L; Wang LX; Tang K
Front Oncol; 2021; 11():710909. PubMed ID: 34568038
[TBL] [Abstract][Full Text] [Related]
12. Deep learning radiomics model based on PET/CT predicts PD-L1 expression in non-small cell lung cancer.
Li B; Su J; Liu K; Hu C
Eur J Radiol Open; 2024 Jun; 12():100549. PubMed ID: 38304572
[TBL] [Abstract][Full Text] [Related]
13. The radiomic biomarker in non-small cell lung cancer:
Wang YB; He X; Song X; Li M; Zhu D; Zhang F; Chen Q; Lu Y; Wang Y
Clin Radiol; 2023 Oct; 78(10):e732-e740. PubMed ID: 37419772
[TBL] [Abstract][Full Text] [Related]
14. Value of pre-therapy
Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Radiomics Nomogram Based on
Yang B; Zhong J; Zhong J; Ma L; Li A; Ji H; Zhou C; Duan S; Wang Q; Zhu C; Tian J; Zhang L; Wang F; Zhu H; Lu G
Front Oncol; 2020; 10():1042. PubMed ID: 32766134
[No Abstract] [Full Text] [Related]
16. Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and
Meng N; Fu F; Sun J; Feng P; Luo Y; Wu Y; Li X; Yuan J; Yang Y; Liu H; Wang Z; Wang M
Quant Imaging Med Surg; 2022 Sep; 12(9):4474-4487. PubMed ID: 36060584
[TBL] [Abstract][Full Text] [Related]
17. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
18.
Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
[TBL] [Abstract][Full Text] [Related]
19. Predictive Power of a Radiomic Signature Based on
Li X; Yin G; Zhang Y; Dai D; Liu J; Chen P; Zhu L; Ma W; Xu W
Front Oncol; 2019; 9():1062. PubMed ID: 31681597
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
